Vicky Nicolaidou

Dr. Vicky Nicolaidou

University of Nicosia, Nicosia, Lefkosía, Cyprus
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
MWMei Mei Wong
Mei Mei Wong
ARAndia N. Redpath
Andia N. Redpath
AEAdel Ersek
Adel Ersek
DBDilair F. Baban
Dilair F. Baban
NHNicole J. Horwood
Nicole J. Horwood
A major therapeutic challenge is how to replace bone once it is lost. Bone loss is a characteristic of chronic inflammatory and degenerative diseases such as rheumatoid arthritis and osteoporosis. Cells and cytokines of the immune system are known to regulate bone turnover by controlling the differentiation and activity of osteoclasts, the bone resorbing cells. However, less is known about the regulation of osteoblasts (OB), the bone forming cells. This study aimed to investigate whether immune cells also regulate OB differentiation. Using in vitro cell cultures of human bone marrow-derived mesenchymal stem cells (MSC), it was shown that monocytes/macrophages potently induced MSC differentiation into OBs. This was evident by increased alkaline phosphatase (ALP) after 7 days and the formation of mineralised bone nodules at 21 days. This monocyte-induced osteogenic effect was mediated by cell contact with MSCs leading to the production of soluble factor(s) by the monocytes. As a consequence of these interactions we observed a rapid activation of STAT3 in the MSCs. Gene profiling of STAT3 constitutively active (STAT3C) infected MSCs using Illumina whole human genome arrays showed that Runx2 and ALP were up-regulated whilst DKK1 was down-regulated in response to STAT3 signalling. STAT3C also led to the up-regulation of the oncostatin M (OSM) and LIF receptors. In the co-cultures, OSM that was produced by monocytes activated STAT3 in MSCs, and neutralising antibodies to OSM reduced ALP by 50%. These data indicate that OSM, in conjunction with other mediators, can drive MSC differentiation into OB. This study establishes a role for monocyte/macrophages as critical regulators of osteogenic differentiation via OSM production and the induction of STAT3 signalling in MSCs. Inducing the local activation of STAT3 in bone cells may be a valuable tool to increase bone formation in osteoporosis and arthritis, and in localised bone remodelling during fracture repair.

19 February 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
LVLiaquat S. Verjee
Liaquat S. Verjee
JVJennifer S. N. Verhoekx
Jennifer S. N. Verhoekx
JCJames K. K. Chan
James K. K. Chan
TKThomas Krausgruber
Thomas Krausgruber
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
JNJagdeep Nanchahal
Jagdeep Nanchahal
Significance: Fibrosis, a hallmark of many clinical disorders, occurs because of uncontrolled myofibroblast activity. We studied Dupuytren's disease, a common hereditable fibrotic condition that causes the fingers to irreversibly curl toward the palm. We found that freshly isolated tissue from Dupuytren's patients contained macrophages and released proinflammatory protein mediators (cytokines). Of the cytokines, only TNF selectively converted normal fibroblasts from the palm of patients with Dupuytren's disease into myofibroblasts via activation of the Wnt signaling pathway. Conversely, blockade of TNF resulted in reversal of the myofibroblast phenotype. Therefore, TNF inhibition may prevent progression or recurrence of Dupuytren's disease.

29 November 2012 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
TPTheresa H Page
Theresa H Page
PCPeter J Charles
Peter J Charles
APAnna Maria Piccinini
Anna Maria Piccinini
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
Peter TaylorPeter Taylor
Peter Taylor
KMKim S. Midwood
Kim S. Midwood
Introduction: The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TNC) are elevated in musculoskeletal disorders including rheumatoid arthritis (RA) and to assess in RA whether levels are related to clinical disease status and/or patient response to treatment. Methods: TNC in serum or plasma was quantified by ELISA. Samples from 4 cohorts of RA patients were examined and compared to normal human subjects and to patients with other inflammatory diseases. Results: Circulating TNC levels were significantly raised in patients with RA, as well as patients with systemic lupus erythematosus, idiopathic inflammatory myositis, psoriatic arthritis and ankylosing spondylitis, whilst patients with Sjogren's syndrome displayed levels similar to healthy controls. The highest levels of TNC were observed in RA patients with late stage disease. In early disease TNC levels correlated positively with ultrasound determined erosion scores. Treatment of early RA patients with infliximab plus methotrexate (MTX) resulted in a transient decrease in circulating TNC over the first year of therapy. In contrast, TNC levels increased over time in RA patients receiving MTX alone. In patients treated with infliximab plus MTX, baseline TNC levels significantly correlated with tender joint counts (TJC) at 18 and 54 weeks after initiation of infliximab therapy. Conclusions: Raised circulating TNC levels are detected in specific inflammatory diseases. Levels are especially high in RA where they may act as a biomarker of bone erosion and a predictor of the effect of infliximab on RA patient joint pain.

24 December 2013 in Leukemia
Verified
Journal Article
Open access
JCJ Chi
J Chi
KNK A Nicolaou
K A Nicolaou
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
LKL Koumas
L Koumas
AMA Mitsidou
A Mitsidou
PCP Costeas
P Costeas
Leukemia is one of the leading journals in hematology and oncology. It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.

1 June 2009 in Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
SHSpencer E. Hall
Spencer E. Hall
AMAllen Mao
Allen Mao
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
Mattéa FinelliMattéa Finelli
Mattéa Finelli
EWEmma L. Wise
Emma L. Wise
NVNagarajan Vaidehi
Nagarajan Vaidehi
Design of dual antagonists for the chemokine receptors CCR2 and CCR5 will be greatly facilitated by knowledge of the structural differences of their binding sites. Thus, we computationally predicted the binding site of the dual CCR2/CCR5 antagonist N-dimethyl-N-[4-[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzohepten-8-yl] carbonyl]amino]benzyl]tetrahydro-2H-pyran-4-aminium (TAK-779), and a CCR2-specific antagonist N-(carbamoylmethyl)-3-trifluoromethyl benzamido-parachlorobenzyl 3-aminopyrrolidine (Teijin compound 1) in an ensemble of predicted structures of human CCR2 and CCR5. Based on our predictions of the protein-ligand interactions, we examined the activity of the antagonists for cells expressing thirteen mutants of CCR2 and five mutants of CCR5. The results show that residues Trp982.60 and Thr2927.40 contribute significantly to the efficacy of both TAK-779 and Teijin compound 1, whereas His1213.33 and Ile2636.55 contribute significantly only to the antagonistic effect of Teijin compound 1 at CCR2. Mutation of residues Trp862.60 and Tyr1083.32 adversely affected the efficacy of TAK-779 in antagonizing CCR5-mediated chemotaxis. Y49A1.39 and E291A7.39 mutants of CCR2 showed a complete loss of CCL2 binding and chemotaxis, despite robust cell surface expression, suggesting that these residues are critical in maintaining the correct receptor architecture. Modeling studies support the hypothesis that the residues Tyr491.39, Trp982.60, Tyr1203.32, and Glu2917.39 of CCR2 form a tight network of aromatic cluster and polar contacts between transmembrane helices 1, 2, 3, and 7.

21 April 2025 in Journal of Peptide Science
Verified
Journal Article
Open access
KAKoulla Achilleos
Koulla Achilleos
CPChristos Petrou
Christos Petrou
Vicky NicolaidouVicky Nicolaidou
Vicky Nicolaidou
Yiannis SarigiannisYiannis Sarigiannis
Yiannis Sarigiannis
Peptides are gaining remarkable popularity in clinical diagnosis and treatment due to their high selectivity and minimal side effects. Over 11% of all new pharmaceutical chemical entities authorised by the FDA between 2016 and 2024 were synthetically manufactured peptides. A critical factor that can potentially limit the efficacy and safety of peptide‐based therapeutics or biologics is immunogenicity, defined as an unintended or adverse immune response to a protein or peptide therapy. This response may be triggered by the peptide itself or by impurities in the production or formulation steps, leading to the production of antidrug antibodies (ADAs). To address this, current regulatory guidelines require the assessment of risks in market authorization applications, which include identifying drug impurity levels and immunogenicity. The development and critical evaluation of appropriate immunogenicity assays is therefore highly warranted. Such assays must consider the fine complexities of the immune response, as well as its variation within the human population. Moreover, immunogenicity testing is expected to remain a priority as the shift toward greener chemistries in peptide synthesis may require reassessment of novel impurities in peptide formulations.